Symmetric dimethylarginine, high-density lipoproteins, and cardiovascular risk assessment: are we ready for clinical use?

There is very good evidence that patients with chronic kidney disease (CKD), particularly those with end-stage renal disease (ESRD), have an increased risk of cardiovascular morbidity and mortality when compared with the general population (1).